To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Division Vote (Commons)
24 Apr 2024 - Regulatory Reform - View Vote Context
Rebecca Long Bailey (Lab) voted Aye - in line with the party majority and in line with the House
One of 131 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 395 Noes - 50
Division Vote (Commons)
24 Apr 2024 - Renters (Reform) Bill - View Vote Context
Rebecca Long Bailey (Lab) voted Aye - in line with the party majority and against the House
One of 136 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 158 Noes - 282
Division Vote (Commons)
24 Apr 2024 - Renters (Reform) Bill - View Vote Context
Rebecca Long Bailey (Lab) voted No - in line with the party majority and against the House
One of 136 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 287 Noes - 144
Division Vote (Commons)
24 Apr 2024 - Renters (Reform) Bill - View Vote Context
Rebecca Long Bailey (Lab) voted No - in line with the party majority and against the House
One of 133 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 283 Noes - 143
Division Vote (Commons)
23 Apr 2024 - Draft Economic Growth (Regulatory Functions) (Amendment) Order 2024 Draft Growth Duty: Statutory Guidance Refresh - View Vote Context
Rebecca Long Bailey (Lab) voted Aye - in line with the party majority and in line with the House
One of 5 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 14 Noes - 1
Division Vote (Commons)
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Rebecca Long Bailey (Lab) voted No - in line with the party majority and against the House
One of 172 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 312 Noes - 237
Division Vote (Commons)
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Rebecca Long Bailey (Lab) voted No - in line with the party majority and against the House
One of 164 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 304 Noes - 222
Division Vote (Commons)
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Rebecca Long Bailey (Lab) voted No - in line with the party majority and against the House
One of 169 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 305 Noes - 234
Division Vote (Commons)
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Rebecca Long Bailey (Lab) voted No - in line with the party majority and against the House
One of 168 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 306 Noes - 229
Written Question
Trastuzumab Deruxtecan: Prices
Monday 22nd April 2024

Asked by: Rebecca Long Bailey (Labour - Salford and Eccles)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to support NHS England to facilitate negotiating a better price for the drug trastuzumab deruxtecan.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

NHS England is responsible for negotiating commercial agreements with individual companies, and the Department encourages companies to come forward with proposals that represent value to the taxpayer. The National Institute for Health and Care Excellence (NICE) published final draft guidance for appeal on the use of trastuzumab deruxtecan for the treatment of HER2-low metastatic or unresectable breast cancer after chemotherapy, and was unable to recommend it as a clinically and cost effective use of National Health Service resources at the price offered by the company. Following extensive discussions through late 2023 and into 2024, NHS England is no longer engaged in any active commercial negotiations on this topic, but remains available to work with the NICE, should AstraZeneca and Daiichi Sankyo be willing to offer trastuzumab deruxtecan at a price that represents value to the NHS.